All In Biotech

Drug Trial Radar · NCT05023486

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

121

Actual

Start

Dec 7, 2021

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Novita Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.

Conditions

  • Advanced or Metastatic Solid Tumor Malignancies

Interventions

  • NP-G2-044 MonotherapyDrug

    1600 mg QD, 2000mg QD, and 2100 mg QD

  • Anti-PD-1 TherapyDrug

    previously initiated per standard of care, at a dose and frequency in accordance with the package insert

  • NP-G2-044 Combination therapyDrug

    1600 mg QD or 2100 mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)Time frame: 6 months
  2. Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapyTime frame: Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)
  3. NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1Time frame: 24 months
  4. Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapyTime frame: 9 months
  5. Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapyTime frame: Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)
  6. NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1Time frame: 24 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • University of Arizona - Cancer Center

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • City of Hope

    Duarte, California

  • City of Hope Irvine Lennar

    Irvine, California

  • Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates

    Newport Beach, California

  • Nuvance Health

    Norwalk, Connecticut

  • University of Florida (UF) - Shands Cancer Center

    Gainesville, Florida

  • Indiana University (IU) Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • University of Kansas Cancer Center

    Fairway, Kansas

  • Henry Ford Health System

    Detroit, Michigan

  • Atlantic Health System - Morristown Medical Center

    Morristown, New Jersey

  • University of Cincinnati (UC) - Cancer Institute

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Texas Southwestern

    Dallas, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Commonwealth University - Massey Cancer Center

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.